Research · PMID 38907684 · Landmark study
Reviewed by Neal Rouzier, MD, Preventive Medicine · Sep 2026
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.
Diabetes care · August 2024 · Ildiko Lingvay, John Deanfield, Steven E Kahn, Peter E Weeke, Hermann Toplak, et al.
What this study found
In people with overweight or obesity and established atherosclerotic cardiovascular disease but not diabetes, semaglutide reduced cardiovascular events irrespective of baseline HbA1c or change in HbA1c. Thus, semaglutide is expected to confer cardiovascular benefits in people with established atherosclerotic cardiovas…
Why this trial matters
SELECT prespecified analysis
How RAGMD uses this study
Clinical questions this paper informs
Synthesis lives on the evidence question — this page shows where the study sits in that analysis.
Supporting literature
Do GLP-1 receptor agonists reduce major cardiovascular events?
GLP-1 receptor agonists with cardiovascular outcome trials (including liraglutide and semaglutide in selected populations) reduce major adverse cardiovascular events beyond glucose lowering in high-risk patients with type 2 diabetes or obesity.
Open evidence analysis